BELGRADE, MT / ACCESSWIRE / May 2, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the quarter ended March 31, 2018, after the close of the financial markets on Tuesday, May 8, 2018.An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and Laura Kendall, Interim Chief Financial Officer…

BELGRADE, MT / ACCESSWIRE / April 18, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has entered into an agreement with Healthcare International Partners (HIP), in Miramar, Florida for expanding distribution in Latin American markets. The three-year agreement with HIP will focus on executing Xtant Medical's global strategy, supporting current distribution partners, recruiting partn…

BELGRADE, MT / ACCESSWIRE / April 17, 2018 / Xtant™ Medical Holdings, Inc. (NYSE American: XTNT) announced today that it has set April 27, 2018 as the record date for a proposed rights offering of its shares of common stock.At the commencement of the rights offering, each holder of common stock will receive 0.0869816 non-transferable subscription rights for each share of common stock held on the record date. Each whole subscription right will entitle the holder to purchase one share of the …

BELGRADE, MT / ACCESSWIRE / April 2, 2018 / Xtant™ Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported its financial results for the period ended December 31st, 2017.''2017 represented a significant year for the Company as we completed transformational restructuring activities that were necessary for the future growth of Xtant Medical,'' said Carl O'Connell, Chief Executive Officer, ''Our team has wo…

BELGRADE, MT / ACCESSWIRE / March 27, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2017, after the close of the financial markets on Monday, April 2, 2018.An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and Laura Kendall, Int…

Reports Pro Forma Stockholders’ Equity of approximately $47.4M as of 2/15/18 Xtant has regained compliance with the NYSE American listing standards BELGRADE, Mont., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today reported a positive stockholders’ equity of approximately $47.4M as of February 15, 2018, on an unaudited, pro forma basis, which reflects Xtant’s: (…

Exchange of $70.238M (plus interest) of convertible notes into 10,401,309 shares of common stock at $7.20 per share. $6.809M Private Placement representing 945,819 shares of common stock at $7.20 per share. BELGRADE, Mont., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the exchange of Xtant’s outstanding 6.00% convertible senior unsecured notes due 202…

Approval of the issuance of new shares of common stock, as required by the NYSE American. Approval of an amendment to its certificate of incorporation, enabling its previously announced 1:12 reverse stock split. Approval of new directors to serve on its board. BELGRADE, Mont., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the results of its Special Meeti…

Conversion of $1.627M (plus interest) of convertible notes into common stock Exchange of $70.238M (plus interest) of convertible notes into common stock Upon stockholder approval, amendment of Certificate of Incorporation to effect reverse stock split of common stock Private placement of approximately $6.809M of common stock Completion of transaction anticipated to allow Xtant to meet liquidity needs and reposition itself for long-term growth. BELGRADE, Mont., Jan. 18, 2018 (GLOBE NEWSWIRE) -…

Company restructuring efforts continue to gain traction towards profitability Third Quarter 2017 Highlights Reported third quarter 2017 revenue of $19.8 million compared to $23.1 million reported during the third quarter of 2016 Operating Expenses decreased 17% to $14.9 million, compared to $17.9 million reported during the third quarter of 2016 Third quarter 2017 EBITDA of $1.4 million compared to $0.7 million reported during the third quarter of 2016   Company management to host conference…

BELGRADE, Mont., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has postponed the release of its third quarter 2017 financial results, originally scheduled for Wednesday, November 8, 2017, and conference call, originally scheduled for Thursday, November 9, 2017. The Company now plans to release its third quarter 2017 financial results in conjunction with t…

BELGRADE, Mont., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced it has entered into a distribution agreement with curasan, Inc. adding a premium line of synthetic scaffolds to its biologics portfolio.  Matriform, Xtant’s brand of the curasan synthetic product portfolio for orthopedic applications, consists of a composition of pure phase Beta-Tricalcium Ph…